- Home
- EMO vs PHAR Comparison
EMO vs PHAR Comparison
Compare EMO & PHAR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EMO
- PHAR
- Stock Information
- Founded
- EMO 2011
- PHAR 1988
- Country
- EMO United States
- PHAR Netherlands
- Employees
- EMO N/A
- PHAR N/A
- Industry
- EMO Investment Managers
- PHAR Biotechnology: Pharmaceutical Preparations
- Sector
- EMO Finance
- PHAR Health Care
- Exchange
- EMO Nasdaq
- PHAR Nasdaq
- Market Cap
- EMO 599.1M
- PHAR 618.3M
- IPO Year
- EMO N/A
- PHAR N/A
- Fundamental
- Price
- EMO $50.61
- PHAR $8.42
- Analyst Decision
- EMO
- PHAR Strong Buy
- Analyst Count
- EMO 0
- PHAR 3
- Target Price
- EMO N/A
- PHAR $27.00
- AVG Volume (30 Days)
- EMO 27.1K
- PHAR 5.6K
- Earning Date
- EMO 01-01-0001
- PHAR 03-13-2025
- Dividend Yield
- EMO 6.70%
- PHAR N/A
- EPS Growth
- EMO N/A
- PHAR N/A
- EPS
- EMO N/A
- PHAR N/A
- Revenue
- EMO N/A
- PHAR $285,745,000.00
- Revenue This Year
- EMO N/A
- PHAR $20.08
- Revenue Next Year
- EMO N/A
- PHAR $9.22
- P/E Ratio
- EMO N/A
- PHAR N/A
- Revenue Growth
- EMO N/A
- PHAR 30.64
- 52 Week Low
- EMO $26.42
- PHAR $6.65
- 52 Week High
- EMO $40.17
- PHAR $13.20
- Technical
- Relative Strength Index (RSI)
- EMO 56.82
- PHAR 40.05
- Support Level
- EMO $48.86
- PHAR $7.95
- Resistance Level
- EMO $50.30
- PHAR $9.35
- Average True Range (ATR)
- EMO 1.16
- PHAR 0.52
- MACD
- EMO -0.11
- PHAR -0.16
- Stochastic Oscillator
- EMO 61.09
- PHAR 22.76
About EMO ClearBridge Energy Midstream Opportunity Fund Inc.
ClearBridge Energy Midstream Opportunity Fund Inc is a non-diversified, closed-end management investment company. Its investment objective is to provide long-term investors with a high level of total return with an emphasis on cash distributions.
About PHAR Pharming Group N.V.
Pharming Group is a global biopharmaceutical company dedicated to transforming the lives of patients with rare, debilitating, and life-threatening diseases. It is commercializing and developing an innovative portfolio of protein replacement therapies and precision medicines to serve the unserved rare disease patients. Its product includes Ruconest. The revenue is generated from the United States.